Cibus (NASDAQ:CBUS – Get Free Report) and Cellectis (NASDAQ:CLLS – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.
Profitability
This table compares Cibus and Cellectis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cibus | -2,258.89% | -287.03% | -27.99% |
| Cellectis | -102.34% | -94.19% | -21.34% |
Risk & Volatility
Cibus has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3, meaning that its stock price is 200% more volatile than the S&P 500.
Earnings and Valuation
This table compares Cibus and Cellectis”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cibus | $3.64 million | 29.71 | -$127.08 million | ($1.65) | -0.86 |
| Cellectis | $79.59 million | 1.54 | -$67.59 million | ($0.65) | -1.88 |
Cellectis has higher revenue and earnings than Cibus. Cellectis is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and price targets for Cibus and Cellectis, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cibus | 1 | 1 | 1 | 0 | 2.00 |
| Cellectis | 2 | 2 | 2 | 1 | 2.29 |
Cibus currently has a consensus target price of $9.00, indicating a potential upside of 536.04%. Cellectis has a consensus target price of $5.46, indicating a potential upside of 345.71%. Given Cibus’ higher probable upside, equities analysts clearly believe Cibus is more favorable than Cellectis.
Insider & Institutional Ownership
33.8% of Cibus shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 29.9% of Cibus shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Cellectis beats Cibus on 11 of the 15 factors compared between the two stocks.
About Cibus
Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. Cibus, Inc. is based in San Diego, California.
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Receive News & Ratings for Cibus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cibus and related companies with MarketBeat.com's FREE daily email newsletter.
